Articles tagged with: Revlimid
News»
A new study appearing in the July 9 issue of Blood discussed a potential therapeutic treatment that focuses on osteoblasts, the cells responsible for bone formation.
Myeloma patients commonly have high serum DKK1 levels, which may decrease with response to therapy for myeloma. DKK1, an important regulator of bone formation, has previously been associated with bone disease in cancers of the esophagus, lungs, prostate, and colon. However, DKK1 has recently emerged as a therapeutic target for suppressed bone formation. The study analyzed the effect of an antibody that neutralizes DKK1, called
News»
Celgene, the manufacturer of Revlimid (lenalidomide), announced today positive results from a Phase 3 clinical trial using Revlimid as first-line therapy for newly diagnosed multiple myeloma patients. Results show that Revlimid in combination with melphalan (Alkeran) and prednisone, followed by continuous Revlimid, significantly improved time to tumor progression.
Check back for further coverage on The Myeloma Beacon.
Update: Please see The Myeloma Beacon's full coverage of Revlimid as a first-line therapy for myeloma.
News, Resources»
Kidney failure, which affects 20 percent of all multiple myeloma patients, is a serious complication that can lead to permanent kidney impairment and continued reliance on dialysis. However, a wide range of treatment options is available to myeloma patients experiencing kidney failure. Successful treatment methods include rehydration, correction of hypercalcemia (a condition that results in high serum calcium levels), and discontinuation of non-steroidal, anti-inflammatory drugs (such as aspirin or ibuprofen), that reduce blood flow to the kidneys.
A common complication found in myeloma patients experiencing kidney failure is hypercalcemia, a disorder that …
NewsFlash »
Celgene Files For Approval Of Revlimid In Japan – On July 7, Celgene announced that it filed a New Drug Application (NDA) for Revlimid (lenalidomide) with the Japanese Ministry of Health, Labour, and Welfare. The application seeks approval for the use of Revlimid in combination with dexamethasone (Decadron) for myeloma patients who have received at least one previous therapy. The filing is based on the results of two large Phase 3 trials from 2007 that demonstrated the efficacy of this treatment regimen. Phase 1 trials with Japanese patients show similar results and also support the NDA. Revlimid is approved in almost 50 countries for the treatment of multiple myeloma. For more information, please visit the Celgene press release.
99th Annual Wamp Swim-a-Thon – On July 18, the International Myeloma Foundation (IMF) is sponsoring a swim-a-thon to benefit the Jeffrey R. Stafford fund at the IMF, used to benefit patients suffering from multiple myeloma. Currently, participants have raised around $100,000 and produced three research grants to aid in research about multiple myeloma. The fund is in honor of Jeffrey Stafford, who was diagnosed with myeloma in 2001. For more information, please visit the IMF Web site.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
News»
The paired use of novel drug agents and autologous stem cell transplantation (ASCT) may not be as effective as formerly believed, according to the June issue of the journal Blood.
Treatment for multiple myeloma commonly integrates high dose therapy of novel drug agents with ASCT. However, an article printed in Blood shows that initial treatment with Revlimid (lenalidomide), one of the novel drug agents, corresponds with inhibition of stem cell mobilization and collection for ASCT.
The introduction of novel drug agents, including thalidomide (Thalomid), Revlimid, and Read the full story »
NewsFlash »
San Diego International Triathlon – On June 28, the 26th annual San Diego International Triathlon will begin at 5:15 a.m. and end at noon. The race will be held at Spanish Landing Park, and The Leukemia & Lymphoma Society's Team In Training (TNT) will be participating. The race benefits St. Vincent de Paul Village, America’s top rehabilitation center for homeless and those in need. To join Team In Training for the triathlon, visit the TNT Web site.
The Price Of Life – Directed by Adam Wishart, this BBC documentary is the first to film the decision-making process of the National Institute for Health and Clinical Excellence (NICE). NICE is an independent organization that provides medical opinions to the National Health Service (NHS), the government-funded health care system in the U.K. The documentary gives insight into NICE’s process of deciding whether or not Revlimid (lenalidomide) should be approved for use and funded by the NHS. It also gives the perspective of patients and an American drug company. For more information, please visit BBC Web site.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
News»
In England and Wales, the National Institute for Health and Clinical Excellence (NICE) has finalized guidelines for the use of Revlimid (lenalidomide) in combination with dexamethasone (Decadron). The guidelines recommend the use of Revlimid for myeloma patients who have already received two or more prior therapies.
NICE is an independent organization that provides medical opinions to the National Health Service (NHS), the government-funded health care system in the U.K.
Based on NICE’s recommendation, the NHS will only pay for Revlimid for patients who have received at least two prior therapies. …
